GSK-25

• CAT Number: I017522
• CAS Number: 874119-56-9
• Molecular Formula: C₂₄H₁₆Cl₂F₂N₆O
• Molecular Weight: 513.33
• Purity: ≥95%
• IUPAC Name: 4-(4-chloro-2-fluorophenyl)-2-(2-chloropyridin-4-yl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxamide
• InChI: InChI=1S/C24H16Cl2F2N6O/c1-11-21(24(35)32-19-6-13-10-30-34-18(13)9-17(19)28)22(15-3-2-14(25)8-16(15)27)33-23(31-11)12-4-5-29-20(26)7-12/h2-10,22H,1H3,(H,30,34)(H,31,33)(H,32,35)
• InChIKey: KZYAHEIPPAPADQ-UHFFFAOYSA-N
• SMILES: CC1=C(C(N=C(N1)C2=CC(=NC=C2)Cl)C3=C(C=C(C=C3)Cl)F)C(=O)NC4=C(C=C5C(=C4)C=NN5)F

GSK-25（Cat No.:I017522）is a small molecule inhibitor of the protein kinase GSK-3 (glycogen synthase kinase 3), specifically targeting its beta isoform (GSK-3β). By inhibiting GSK-3β, GSK-25 modulates various signaling pathways involved in cell proliferation, differentiation, and survival. This compound is being studied for its potential therapeutic applications in neurodegenerative diseases, such as Alzheimer’s, as well as in cancer, where GSK-3β is often dysregulated. Ongoing research aims to explore GSK-25’s efficacy in restoring normal cellular functions and its potential in combination therapies to enhance treatment outcomes.

Reference

[1]. Sehon CA, et al. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. J Med Chem. 2008 Nov 13;51(21):6631-4.